公开(公告)号：US20220183292A1

公开(公告)日：2022-06-16

申请号：US17603086

申请日：2020-03-16

申请人： ECOLE POLYTECHNIQUE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  SORBONNE UNIVERSITE

发明人： Bastien NAY ,  Emmanuel BAUDOUIN ,  Wei Zhang

IPC分类号： A01N43/22 ,  A01P13/00

摘要： The invention relates to the use, as a herbicide, of at least one compound chosen from the compounds of general formula (I) and organic or inorganic salts thereof and isomers thereof.
The invention also relates to a phytotoxic composition and to a method for controlling the development of and/or treating undesirable plants on the surface of a target zone.

公开(公告)号：US11359027B2

公开(公告)日：2022-06-14

申请号：US16312647

申请日：2017-06-22

申请人： UNIVERSITE PARIS EST CRETEIL VAL DE MARNE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS ,  SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Sébastien Maury ,  José Cohen ,  Benoît Salomon ,  Sina Naserian ,  Mathieu Leclerc

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61K45/06

摘要： The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

公开(公告)号：US20220160716A1

公开(公告)日：2022-05-26

申请号：US17439995

申请日：2020-03-20

申请人： SORBONNE UNIVERSITE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS) ,  MANROS THERAPEUTICS

发明人： Thomas FALGUIERES ,  Virginie VAUTHIER ,  Laurent MEIJER ,  Nassima OUMATA

IPC分类号： A61K31/52 ,  A61P1/16

摘要： A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.

公开(公告)号：US20220154153A1

公开(公告)日：2022-05-19

申请号：US17439641

申请日：2020-03-21

申请人： Université de Paris ,  Sorbonne Universite ,  Centre National de la Recherche Scientifique ,  Institut National de la Sante et de la Recherche Medicale

发明人： Angelita REBOLLO ,  Pierre TUFFERY ,  Chang-Zhi DONG

IPC分类号： C12N9/12 ,  C07K16/40

摘要： The present invention provides new inhibitors of LRRK2/PP1 interaction. The present invention relates to these inhibitors for use as medicament and more particularly to methods and pharmaceutical compositions for the treatment of neurodegenerative disorders, more particularly α-synucleinopathies.

公开(公告)号：US20220062254A1

公开(公告)日：2022-03-03

申请号：US17354582

申请日：2021-06-22

申请人： ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) ,  SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS) ,  ÉCOLE PRATIQUE DES HAUTES ÉTUDES

发明人： Frédéric DARIOS ,  Giovanni STEVANIN ,  Fanny MOCHEL ,  Julien BRANCHU ,  Maxime BOUTRY

IPC分类号： A61K31/45 ,  A61K31/4025 ,  A61K31/137 ,  A61K31/7068 ,  A61K31/7105 ,  A61K31/5375 ,  A61K45/06

摘要： The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

公开(公告)号：US11229356B2

公开(公告)日：2022-01-25

申请号：US16499386

申请日：2018-03-29

申请人： INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE (ICM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) ,  SORBONNE UNIVERSITE

发明人： Pierre Pouget ,  Pierre Daye ,  Jean Lorenceau

IPC分类号： A61B3/11 ,  A61B3/14 ,  A61B3/06

摘要： Evaluation of the perception of colors by mammals with a view to obtaining a characteristic biomarker of each tested subject takes advantage of the slow pupillary oscillatory response to generate an objective neurological signature of this perception of colors. A method based on pupil frequency tagging is used at a tagging frequency Ftag adapted to the pupil response speed. A dynamic two-color stimulus is displayed, this stimulus comprising a two-color pattern the colors of which are inverted at the frequency Ftag, one of the colors gradually varying in a range of possible values. From the pupillary response, a signal representative of the oscillation power of the pupil is generated. The minimum of this signal corresponds to the relative iso-luminance of the tested pair of colors.

公开(公告)号：US11224586B2

公开(公告)日：2022-01-18

申请号：US16342610

申请日：2017-10-18

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Universite ,  Universite de Poitiers ,  Centre Hospitalier Universitaire de Poitiers

发明人： Stéphane Bach ,  Marie-Thérèse Dimanche-Boitrel ,  Claire Delehouze ,  Thierry Hauet

IPC分类号： A61K31/352 ,  A61K45/06 ,  A61P27/02 ,  A61P25/00 ,  C07D311/20 ,  C07D311/54

摘要： The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

公开(公告)号：US20220013772A1

公开(公告)日：2022-01-13

申请号：US17284202

申请日：2019-10-10

申请人： RENAULT s.a.s. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  COLLEGE DE FRANCE ,  SORBONNE UNIVERSITE

发明人： Mohamed CHAKIR ,  Sathiya MARIYAPPAN ,  Jean-Marie TARASCON ,  Qing WANG

IPC分类号： H01M4/525 ,  H01M4/505 ,  H01M10/054 ,  H01M4/62 ,  H01M10/44 ,  H01M4/04

摘要： A positive electrode active material for a sodium-ion battery has the following formula: NaxNi0.5-yCuyMn0.5-zTizO2, in which: -x varies from 0.9 to 1; -y varies from 0.05 to 0.1; -z varies from 0.1 to 0.3. When z is equal to 0.1 and x is equal to 1, then y is not equal to 0.05.

公开(公告)号：US20220006409A1

公开(公告)日：2022-01-06

申请号：US17292561

申请日：2019-11-07

申请人： SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Vincent HAYWARD ,  Sinan HALIYO ,  Stéphane REGNIER ,  Antoine WEILL DUFLOS

IPC分类号： H02P25/032 ,  G08B6/00

摘要： An interface with haptic force feedback, including a controller arranged and/or programmed to receive an initial command designed to control an actuator so that a force exerted by the actuator is equal to an initial low-frequency part F0(t) plus an optional high-frequency part; the initial command transformed into a command in which the initial low-frequency part F0(t) is transformed into a modified low-frequency part F(t) which follows in amplitude a decreasing function and for which, over any time interval of duration Δt between an instant t and an instant t+Δt, the modified low-frequency part F(t) decreases by a value X of less than or equal to 10% of the initial value of the modified low-frequency part of the force F(t) at the instant t, the duration Δt of the time interval being greater than or equal to 0.3 second; control the actuator according to the transformed command.

公开(公告)号：US20210401944A1

公开(公告)日：2021-12-30

申请号：US17294079

申请日：2019-11-18

申请人： 4MOVING BIOTECH ,  SORBONNE UNIVERSITE

发明人： Francis BERENBAUM ,  Revital RATTENBACH

IPC分类号： A61K38/26 ,  A61P19/02 ,  A61K47/42 ,  A61K9/00

摘要： A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and/or stem cell differentiation into chondrocytes.